Moderately Escalated Hypofractionated (Chemo)Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer

Purpose To assess clinical outcomes and toxicities in patients with stage III unresectable non-small cell lung cancer (NSCLC) treated with a moderately escalated hypofractionated radiotherapy delivered with Helical Intensity-Modulated Technique in combination with sequential or concurrent chemothera...

Full description

Bibliographic Details
Main Authors: Vittorio eDonato, Stefano eArcangeli, Alessia eMonaco, Cristina eCaruso, Michele eCianciulli, Genoveva eBoboc, Cinzia eChiostrini, Roberta eRauco, Maria Cristina ePressello
Format: Article
Language:English
Published: Frontiers Media S.A. 2013-11-01
Series:Frontiers in Oncology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00286/full
id doaj-b846f4b378b5436db9a7057ff9a92a30
record_format Article
spelling doaj-b846f4b378b5436db9a7057ff9a92a302020-11-24T22:15:15ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2013-11-01310.3389/fonc.2013.0028663430Moderately Escalated Hypofractionated (Chemo)Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung CancerVittorio eDonato0Stefano eArcangeli1Alessia eMonaco2Cristina eCaruso3Michele eCianciulli4Genoveva eBoboc5Cinzia eChiostrini6Roberta eRauco7Maria Cristina ePressello8Azienda Ospedaliera S.Camillo-ForlaniniAzienda Ospedaliera S.Camillo-ForlaniniAzienda Ospedaliera S.Camillo-ForlaniniAzienda Ospedaliera S.Camillo-ForlaniniAzienda Ospedaliera S.Camillo-ForlaniniAzienda Ospedaliera S.Camillo-ForlaniniAzienda Ospedaliera S.Camillo-ForlaniniAzienda Ospedaliera S.Camillo-ForlaniniAzienda Ospedaliera S.Camillo-ForlaniniPurpose To assess clinical outcomes and toxicities in patients with stage III unresectable non-small cell lung cancer (NSCLC) treated with a moderately escalated hypofractionated radiotherapy delivered with Helical Intensity-Modulated Technique in combination with sequential or concurrent chemotherapy.Methods and Materials Sixty-one consecutive patients considered non-progressive after 2 cycles of induction chemotherapy were treated with a moderately escalated hypofractionated radiation course of 30 daily fractions of 2.25-2.28 Gy each administered in 6 weeks up to a total dose of 67.5 Gy–68.4 Gy (range, 64.5 Gy–71.3 Gy). Thirty-two received sequential RT after 2 more cycles (total= 4 cycles) of chemotherapy, while twenty-nine were treated with concurrent chemo-radiation. The target was considered the gross tumour volume and the clinically proven nodal regions, without elective nodal irradiation. Results With a median follow up of 27 months (range 6 to 40), one-year and 2-year OS rate for all patients was 77% and 53% respectively, with a median survival duration of 18.6 months in the sequential group and 24.1 months in the concomitant group. No Grade ≥ 4 acute and late toxicity was reported. Acute Grade 3 treatment-related pneumonitis was detected in 10% of patients. Two patients, both receiving the concurrent schedule, developed a Grade 3 acute esophagitis. The overall incidence of late Grade 3 lung toxicity was 5%. No patients experienced a Grade 3 late esophageal toxicity.Conclusions A moderately hypofractionated radiation course delivered with a Helical Intensity-Modulated Technique is a feasible treatment option for patients with unresectable locally advanced NSCLC receiving chemotherapy (sequentially or concurrently). Hypofractionated radiotherapy with a dedicated technique allows safely dose escalation, minimizing the effect of tumor repopulation that may occur with prolonged treatment time.http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00286/fullDose EscalationchemoradiationHypofractionated RadiotherapyUnresectable NSCLCHelical Tomotherapy
collection DOAJ
language English
format Article
sources DOAJ
author Vittorio eDonato
Stefano eArcangeli
Alessia eMonaco
Cristina eCaruso
Michele eCianciulli
Genoveva eBoboc
Cinzia eChiostrini
Roberta eRauco
Maria Cristina ePressello
spellingShingle Vittorio eDonato
Stefano eArcangeli
Alessia eMonaco
Cristina eCaruso
Michele eCianciulli
Genoveva eBoboc
Cinzia eChiostrini
Roberta eRauco
Maria Cristina ePressello
Moderately Escalated Hypofractionated (Chemo)Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer
Frontiers in Oncology
Dose Escalation
chemoradiation
Hypofractionated Radiotherapy
Unresectable NSCLC
Helical Tomotherapy
author_facet Vittorio eDonato
Stefano eArcangeli
Alessia eMonaco
Cristina eCaruso
Michele eCianciulli
Genoveva eBoboc
Cinzia eChiostrini
Roberta eRauco
Maria Cristina ePressello
author_sort Vittorio eDonato
title Moderately Escalated Hypofractionated (Chemo)Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer
title_short Moderately Escalated Hypofractionated (Chemo)Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer
title_full Moderately Escalated Hypofractionated (Chemo)Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer
title_fullStr Moderately Escalated Hypofractionated (Chemo)Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer
title_full_unstemmed Moderately Escalated Hypofractionated (Chemo)Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer
title_sort moderately escalated hypofractionated (chemo)radiotherapy delivered with helical intensity-modulated technique in stage iii unresectable non-small cell lung cancer
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2013-11-01
description Purpose To assess clinical outcomes and toxicities in patients with stage III unresectable non-small cell lung cancer (NSCLC) treated with a moderately escalated hypofractionated radiotherapy delivered with Helical Intensity-Modulated Technique in combination with sequential or concurrent chemotherapy.Methods and Materials Sixty-one consecutive patients considered non-progressive after 2 cycles of induction chemotherapy were treated with a moderately escalated hypofractionated radiation course of 30 daily fractions of 2.25-2.28 Gy each administered in 6 weeks up to a total dose of 67.5 Gy–68.4 Gy (range, 64.5 Gy–71.3 Gy). Thirty-two received sequential RT after 2 more cycles (total= 4 cycles) of chemotherapy, while twenty-nine were treated with concurrent chemo-radiation. The target was considered the gross tumour volume and the clinically proven nodal regions, without elective nodal irradiation. Results With a median follow up of 27 months (range 6 to 40), one-year and 2-year OS rate for all patients was 77% and 53% respectively, with a median survival duration of 18.6 months in the sequential group and 24.1 months in the concomitant group. No Grade ≥ 4 acute and late toxicity was reported. Acute Grade 3 treatment-related pneumonitis was detected in 10% of patients. Two patients, both receiving the concurrent schedule, developed a Grade 3 acute esophagitis. The overall incidence of late Grade 3 lung toxicity was 5%. No patients experienced a Grade 3 late esophageal toxicity.Conclusions A moderately hypofractionated radiation course delivered with a Helical Intensity-Modulated Technique is a feasible treatment option for patients with unresectable locally advanced NSCLC receiving chemotherapy (sequentially or concurrently). Hypofractionated radiotherapy with a dedicated technique allows safely dose escalation, minimizing the effect of tumor repopulation that may occur with prolonged treatment time.
topic Dose Escalation
chemoradiation
Hypofractionated Radiotherapy
Unresectable NSCLC
Helical Tomotherapy
url http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00286/full
work_keys_str_mv AT vittorioedonato moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT stefanoearcangeli moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT alessiaemonaco moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT cristinaecaruso moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT micheleecianciulli moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT genovevaeboboc moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT cinziaechiostrini moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT robertaerauco moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT mariacristinaepressello moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
_version_ 1725795139451879424